Precision Medicines Targeting the
Dark Genome
We are leveraging the power of the dark genome to develop precise and potent RNA therapies for reprogramming disease driving cell-states.
Latest News
HAYA Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform
Latest News
HAYA Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform
Our mission is to identify and address the RIGHT...
Accelerating the development of the next-generation of dark genome targets and therapeutics for underserved rare and chronic diseases.
Target
Dark Genome derived regulatory RNAs
Place
Diseased tissues & cells identified with proprietary tools & methods
Time
Targeting lncRNAs processes & integration of environmental signals when modulating the epigenome
Way
Emerging RNA-targeting modalities, such as modified antisense oligonucleotides (ASOs), to target and inhibit proprietary lncRNAs to prevent and reverse disease
Supporters & Awards
A short list of our supporters and awards
